Why Strides Pharma is falling today has become a common question among investors watching this pharmaceutical stock. As of mid December 2025, Strides Pharma Science Ltd has been experiencing volatility in its share price.
The stock has been trading below key moving averages and showing signs of weakness despite strong operational performance. Many investors are concerned about recent price movements, especially after the company completed its OneSource demerger in early December.
The pharmaceutical sector has been facing broader market challenges and Strides Pharma has not been immune to these headwinds. While the company maintains solid fundamentals and impressive long term returns, short term technical indicators suggest caution for traders.
Key Takeaways
- Strides Pharma trading below 5 day and 20 day moving averages indicating short term weakness
- Stock underperforming its pharma sector peers by approximately 2 percent in recent sessions
- OneSource demerger completed with record date set for December 6, 2024
- Company maintains strong quarterly profitability with nine consecutive profitable quarters
- Long term performance remains robust with 439 percent returns over three years
- Delivery volume dropped significantly showing reduced investor participation
- Market capitalization stands at approximately Rs 7,672 crore as midcap pharma player
Also Read: Why Akums Drugs Share Is Falling Today – Complete Market Analysis
Recent Price Action and Market Performance
Strides Pharma has been experiencing downward pressure in recent trading sessions. The stock has been consistently underperforming compared to benchmark indices. Technical analysis shows the stock trading below its short term moving averages creating bearish signals for traders.
The 5 day and 20 day averages have turned into resistance levels. However, the stock remains above its 200 day moving average which suggests the long term trend is still intact.
Market participants have noticed a significant drop in delivery based trading volumes. This decline of over 70 percent compared to recent averages indicates that investors are not building fresh positions. Lower delivery volumes often signal lack of confidence and increased speculative trading rather than investment oriented buying.
Impact of OneSource Demerger
The OneSource demerger has been a major corporate action for Strides Pharma. The company separated its CDMO business into a new listed entity with shareholders receiving one OneSource share for every two Strides shares held. The record date was December 6, 2024 and listing happened in January 2025.
This corporate restructuring created uncertainty among investors about valuations. The market needed time to assess the fair value of both entities post demerger. OneSource Specialty Pharma reported strong Q2 FY26 performance with revenue growing 12 percent to Rs 376 crore and EBITDA improving 37 percent. Despite positive metrics, the demerger process contributed to price adjustments.
Fundamental Strength Versus Technical Weakness
Strides Pharma continues to demonstrate solid operational performance despite stock price weakness. The company has reported positive quarterly results for nine consecutive quarters with profitability metrics reaching record highs. Operating profit to interest ratio stands at 5.02 times indicating healthy financial management.
Long term investors have been rewarded with returns of 439 percent over three years and 138 percent over five years. These numbers significantly outperform broader market indices. However, short term traders are concerned about recent price action and technical breakdown of support levels. The return on capital employed of 15.6 percent reflects effective capital utilization.
Sector Dynamics and What Lies Ahead
The pharmaceutical sector has been facing mixed sentiment in recent months. Regulatory challenges, pricing pressures and competition continue to impact the sector. Strides operates in regulated markets requiring constant compliance which can quickly impact stock prices during any concerns.
Investors should monitor OneSource performance post listing, new product approvals and quarterly results. Technical traders will watch for the stock to reclaim short term moving averages. A move above 20 day average with good volumes would signal potential reversal. The company’s ability to maintain profitable quarters while managing costs will be crucial for restoring investor confidence.
Tags: Strides Pharma falling, Strides Pharma stock, pharmaceutical stocks India, OneSource demerger, midcap pharma stocks, stock market analysis, Strides share price
[…] Also Read: Why Strides Pharma Is Falling Today: Understanding the Recent Stock Movement […]